Eli Lilly is a safer way to capitalize on AI-driven drug discovery.

A new research paper reframes the simulation hypothesis, asking whether reality could be simulated and what science can test.

Nvidia's restraint — focusing on enabling the ecosystem rather than owning it — has helped cement its role as the ...

This problem was introduced by Leslie Lamport in his paper The Byzantine Generals Problem, where he describes the problem as follows: “Reliable computer systems must handle malfunctioning components ...

Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

When I last covered the self-styled TechBio company Recursion Pharmaceuticals, Inc. (RXRX) in early October, I was attempting to find reasons why the company's share price was on the rise, up from ~$4 ...

Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...

Recursion Pharmaceuticals Inc has faced significant challenges in its financial performance, highlighted by a sharp decline in revenue growth, which fell to -32.98% in Q3 2025 from +30.14% in Q2 2025.

Condé Nast Traveler readers believe this major US city is the end-all-be-all for shopping destinations in the country.